Impact factors of benefiting from initial 131I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response

Abstract

Objective This study was carried out to confirm whether patients with intermediate-risk differentiated thyroid cancer (DTC) could benefit from initial 131I ablation and to identify the factors that impacted the benefit. Methods We retrospectively assessed a cohort of 548 patients with intermediate-risk DTC who were classified into structural incomplete response (SIR), biochemical incomplete response (BIR), indeterminate response (IDR), and excellent response (ER) groups according to the ATA guidelines (version 2015). A downgrade in the classification, such as from initial SIR to final BIR, IDR, or ER, from BIR to IDR or ER, and from initial IDR to final ER, was defined as benefiting from initial 131I ablation (benefit group). Non-downgraded classification meant non-benefit. Results 64.78% of patients benefited from the initial 131I ablation in the final re-evaluation. Gender (OR = 0.038, P = 0.002), interval time (OR = 0.038, P = 0.002) and serum ps-Tg (OR = 0.961, P = 0.001) were independent prognostic factors for benefiting from initial 131I ablation, with the cutoff value were 5 months and 19.08 ng/ml. Conclusion Patients with intermediate-risk DTC could benefit from initial 131I ablation. Female patients with intermediate-risk DTC whose interval time <5 months and ps-Tg <19.08 ng/ml were more likely to benefit. Early 131I ablation for such patients is beneficial for achieving a complete therapeutic response.